GHK-Cu combines a three-amino-acid peptide with copper; BPC-157 is a separate fifteen-amino-acid peptide. GHK-Cu has been tested in specific topical skin and wound products, with mixed human results. BPC-157 has repair-related cell and animal findings and small human reports. No direct GHK-Cu–BPC-157 trial was identified, so these sources cannot establish which improves skin or injury recovery more.
Research reviewed October 15, 2026. Educational information only.
Two peptides studied through different preparations
GHK-Cu consists of glycyl–histidyl–lysine coordinated with copper. Copper can exchange among molecular partners in solution, so the complete preparation matters when interpreting a test. BPC-157 has the fifteen-residue sequence GEPPPGKPADDAGLV. Its free base and acetate salt are chemically distinct forms, and FDA’s identity assessment notes inconsistencies in some supplied descriptions. The names do not identify interchangeable treatments.
The useful comparison begins with what investigators actually measured: collagen production in cells, ulcer area in patients, the force needed to break a repaired rat tendon, or a patient’s report of pain. Each observation answers a different part of tissue repair. No study located for this review randomly assigned people to GHK-Cu versus BPC-157 for the same condition.
The main differences
What exactly are the two compounds?
Sequence, copper binding and salt form identify the tested material; a shared tissue-repair claim does not make the molecules interchangeable.
GHK-Cu
GHK-Cu is the copper complex of glycyl–histidyl–lysine, a three-amino-acid peptide. Solution studies describe more than one copper-containing species, so a complete formulation is relevant to the experiment.
BPC-157
BPC-157 is the fifteen-amino-acid peptide GEPPPGKPADDAGLV. FDA evaluates its free base and acetate salt separately; the salt description and product characterization matter when assigning a result.
What physically changed in the cell experiments?
These were separate laboratory studies. Fibroblasts make connective-tissue proteins; the BPC-157 experiments used rat tendon tissue and tendon-derived cells.
GHK-Cu
GHK-Cu-exposed fibroblasts made more collagen without an increase in cell number in Maquart and colleagues’ culture experiment. The study measured protein production, without measuring human wound strength or wrinkle reduction.
BPC-157
In Chang and colleagues’ rat-tendon experiments, more cells grew from treated tissue pieces, and treated cells moved, spread and survived oxidative stress better. BPC-157 did not directly increase proliferation in that test. Human injury recovery was not measured.
Which preparations have measured outcomes in people?
The human reports concern different conditions and measurements. They are not a direct GHK-Cu–BPC-157 comparison.
GHK-Cu
In a diabetic-foot-ulcer study, ulcers on the soles of the feet shrank by a median 98.5% with GHK-copper gel versus 60.8% with comparison gel without GHK-Cu, alongside standardized care. The abstract omits the patient count, assessment time and confidence interval. A separate venous-ulcer trial did not establish greater ulcer-size reduction with copper cream than with cream without peptide.
Sources
- Mulder GD, Patt LM, Sanders L, Rosenstock J, Altman MI, Hanley ME, Duncan GW. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society. 1994;2(4):259–269. DOI: 10.1046/j.1524-475X.1994.20406.x.
- Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, Heggers JP, Hill DP, Taylor EL, Robson MC. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. Journal of vascular surgery. 1992;16(2):251–257. DOI: 10.1067/mva.1992.37086.
BPC-157
A knee-pain chart review reached sixteen respondents, including twelve given BPC-157 alone; eleven of those twelve reported improvement. There was no placebo group or standardized functional assessment. These symptom reports cannot demonstrate tissue repair or estimate an advantage over a GHK-Cu product.
Sources
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021;27(4):8-13. PMID: 34324435.
- U.S. Food and Drug Administration. FDA Briefing Document: Pharmacy Compounding Advisory Committee (PCAC) Meeting, July 23–24, 2026. BPC-157-related bulk drug substances section. 2026.
What do the exposure measurements actually measure?
Copper crossing removed skin and intact peptide in animal blood are different analytes in different systems. An elimination half-life requires a defined compound and a measured concentration decline.
GHK-Cu
Hostynek and colleagues applied a copper–GHK preparation to removed human skin and measured copper over 48 hours. Some crossed and some remained in skin. Measuring the metal does not establish intact GHK-Cu absorption or a human blood half-life.
BPC-157
He and colleagues measured intact BPC-157 in rats and dogs. Intravenous elimination half-life was 15.2 minutes in the rat analysis and 5.27 ± 2.25 minutes in dogs (mean ± standard deviation). The species-specific animal results do not establish human or topical exposure.
Can the sources show which is safer?
A topical clinical observation cannot establish safety by injection, and small reports cannot reliably measure uncommon or delayed reactions.
GHK-Cu
FDA’s GHK-Cu safety-risk entry specifically concerns injectable routes. It notes limited human data and possible immune reactions related to aggregation and peptide impurities. Topical studies do not establish the rate of those injection risks.
BPC-157
FDA found insufficient clinical safety information for BPC-157 and highlighted characterization, aggregation, impurities and possible immune reactions. Small route-specific reports cannot supply a reliable long-term safety comparison with GHK-Cu.
Collagen production and cell movement explain different observations
Maquart and colleagues (1988) found that cultured fibroblasts, connective-tissue cells that produce structural proteins, made more collagen after exposure to GHK-Cu without a corresponding increase in cell number. This is a protein-production result in culture; it does not measure the strength or appearance of a repaired human tissue.
Chang and colleagues (2011) studied BPC-157 in tissue pieces and cells from rat Achilles tendons. More cells grew out from treated tissue, and treated cells moved and spread more readily across culture surfaces. They also survived hydrogen-peroxide stress better. BPC-157 did not directly increase proliferation in that test. These findings help distinguish cell movement and survival from simply making more cells. They supply no direct comparison with the GHK-Cu collagen experiment.
The topical GHK-Cu results depend on the wound and product
Mulder and colleagues (1994) compared a GHK-copper gel with comparison gel without GHK-Cu during standardized care for diabetic neuropathic ulcers. For ulcers on the sole of the foot, the abstract reports median ulcer-area reduction of 98.5% with the copper gel and 60.8% with the gel base (P<0.05). Those numbers describe how much area closed, rather than the proportion of patients whose ulcers healed. The accessible abstract omits the denominator, assessment time and confidence interval, limiting assessment of the magnitude and reliability.
A different trial gives a less favorable result. Bishop and colleagues (1992) reported 86 evaluable completers in a randomized venous-leg-ulcer study comparing copper-tripeptide cream, cream without peptide and silver sulfadiazine cream. Copper-tripeptide cream did not establish greater ulcer-size reduction than its base; silver sulfadiazine reduced ulcer size more than either. A favorable diabetic-ulcer result therefore cannot be generalized to all chronic wounds.
Miller and colleagues (2006) randomized post-laser skin-care regimens with or without GHK-Cu. Among thirteen completers, objective redness, wrinkle and skin-quality assessments did not establish a group advantage at the reported assessments. Patient-rated skin quality favored GHK-Cu (P=0.04). This small procedure-specific study preserves a subjective benefit alongside uncertain objective comparisons.
BPC-157 tendon mechanics and knee symptoms remain distinct
In Biçer and colleagues’ 2026 experiment, researchers cut and surgically repaired Achilles tendons in 32 rats and assigned eight rats each to BPC-157, a TB-500-named product, both products or injection liquid containing neither peptide. Its composition was not specified. On day 30, four tendons per group were pulled until they broke. Tendons from rats given BPC-157 withstood more pulling force before breaking than tendons from rats given neither peptide, but the difference remained too uncertain to establish an effect (adjusted P=0.389). Only the TB-500-to-control comparison met the statistical threshold. That does not establish that TB-500 outperformed BPC-157, and GHK-Cu was not tested.
Lee and Padgett (2021) reviewed seventeen knee-pain treatment records and reached sixteen patients by telephone. Eleven of twelve respondents who had received BPC-157 alone reported improvement; three of four given BPC-157 with a material called TB4 also reported improvement. Without a placebo group or standardized functional and imaging assessment, the reports cannot determine the treatment’s effect or demonstrate repaired cartilage or tendons. These symptom observations cannot be ranked against ulcer-area measurements from different patients.
Pharmacokinetics: skin penetration and blood clearance
Hostynek and colleagues (2010) placed a copper–GHK preparation on removed human skin and followed copper crossing or remaining in the skin over 48 hours. Their assay measured the metal. It did not establish that intact GHK-Cu crossed, nor did it measure a human blood half-life.
He and colleagues (2022) measured intact BPC-157 after intravenous and intramuscular administration in rats and dogs. After intravenous administration, the reported elimination half-life was 15.2 minutes in the rat analysis and 5.27 ± 2.25 minutes in dogs (mean ± standard deviation). A half-life describes the decline of a specified analyte during elimination. These animal blood measurements cannot be compared numerically with copper crossing removed skin, and neither supplies a validated human exposure comparison between the peptides.
The available studies cannot rank their safety
FDA’s 2026 BPC-157 assessment found insufficient clinical safety information. Short rectal-preparation reports, small injection reports and spontaneous adverse-event reports have different routes and limitations. The agency noted potential immune reactions related to peptide aggregation and impurities, without studies formally measuring immunogenicity. BPC-157 is not a component of an FDA-approved drug; an advisory discussion about compounding is a separate regulatory process.
FDA’s current safety-risk record specifically identifies injectable GHK-Cu, citing possible immune reactions associated with aggregation and peptide-related impurities and limited human safety data. Topical wound or cosmetic trials do not determine injection safety. The available evidence cannot show that one peptide has a lower rate of uncommon or delayed harm than the other.
Frequently asked questions
Does more collagen in culture mean better skin healing?
Collagen production is one component of repair. A culture test does not measure organization, strength, infection or healing time in a patient. The human GHK-Cu ulcer trials had different results in different wounds and formulations.
Did the recent rat tendon study compare GHK-Cu with BPC-157?
It compared BPC-157, a supplier TB-500 product, their combination and a no-peptide control after surgical Achilles repair. GHK-Cu was not included. Four tendons per group underwent strength testing on day 30.
Can these results establish a benefit from combining the peptides?
No study identified for this review isolated a GHK-Cu–BPC-157 combination against its individual components and a suitable control. Different biological rationales do not establish a larger clinical benefit or a safe combination.
Is the diabetic-ulcer percentage the percentage of patients healed?
The 98.5% and 60.8% values are median percentage reductions in the area of ulcers on the soles of the feet. They are not the percentage of patients whose ulcers completely healed. The accessible abstract does not state the denominator or assessment time.
Profiles and related reading
References
- Lau SJ, Sarkar B. The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma. The Biochemical journal. 1981;199(3):649–656. DOI: 10.1042/bj1990649.
Solution experiments demonstrated multiple GHK-copper species and albumin competition.
- Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS letters. 1988;238(2):343–346. DOI: 10.1016/0014-5793(88)80509-x.
GHK-Cu increased collagen synthesis in cultured fibroblasts independently of cell-number change.
- Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, Heggers JP, Hill DP, Taylor EL, Robson MC. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. Journal of vascular surgery. 1992;16(2):251–257. DOI: 10.1067/mva.1992.37086.
The venous-ulcer trial did not establish greater ulcer-size reduction with the copper-tripeptide cream than with the carrying cream without peptide; silver sulfadiazine reduced ulcer size more than either cream.
- Mulder GD, Patt LM, Sanders L, Rosenstock J, Altman MI, Hanley ME, Duncan GW. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society. 1994;2(4):259–269. DOI: 10.1046/j.1524-475X.1994.20406.x.
The standardized-care diabetic-ulcer comparison reported greater median plantar-ulcer area closure with GHK-copper gel; the acquired abstract lacked denominator and time point.
- Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of facial plastic surgery. 2006;8(4):252–259. DOI: 10.1001/archfaci.8.4.252.
The 13-completer post-laser study found no objective advantage but a favorable patient-rated skin-quality comparison.
- Hostynek JJ, Dreher F, Maibach HI. Human skin retention and penetration of a copper tripeptide in vitro as function of skin layer towards anti-inflammatory therapy. Inflammation Research. 2010;59(11):983–988. DOI: 10.1007/s00011-010-0214-4.
The final skin-diffusion publication measured copper after applying a cuprate-diacetate preparation, providing a transport observation for copper in excised tissue.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Current agency web record, accessed October 13, 2026.
Agency safety context distinguishes injectable GHK-Cu and the thymosin β4 fragment from other preparations.
- U.S. Food and Drug Administration. FDA Briefing Document: Pharmacy Compounding Advisory Committee (PCAC) Meeting, July 23–24, 2026. BPC-157-related bulk drug substances section. 2026.
FDA's assessment supplies chemical-form identity, historical human-study summaries, clinical-safety context and the agency's evaluation of the available evidence.
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-80. DOI: 10.1152/japplphysiol.00945.2010. PMID: 21030672.
Rat tendon explants and fibroblasts showed greater outgrowth, migration, spreading and stress survival, accompanied by actin and attachment-signaling changes. The proliferation assays were unchanged.
- He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology. 2022;13:1026182. DOI: 10.3389/fphar.2022.1026182. PMID: 36588717.
Intact-peptide measurements established animal intravenous and intramuscular exposure. Separate tritium experiments followed peptide-derived material through metabolism, tissue distribution and excretion.
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021;27(4):8-13. PMID: 34324435.
A knee-treatment chart review reached 16 patients by telephone and recorded reported pain improvement after BPC-157 alone or with thymosin beta-4.
- Biçer O, Adanir O, Güleryüz Y, Balci EC, Dinçel YM, Yenigün MY, Aydin C, Bayrak BY. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery. 2026;37(3):822–837. DOI: 10.52312/jdrs.2026.2951.
After Achilles-tendon cutting and surgical repair in rats, the investigators measured the force needed to break the repaired tendons. The TB-500-labelled group withstood more force than the no-peptide vehicle group, but the publication does not establish its peptide sequence or chemical form.